PKCα expression is a marker for breast cancer aggressiveness

Gry K. Lønne, Louise Cornmark, Iris O. Zahirovic, Göran Landberg, Karin Jirström, Christer Larsson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Background: Protein kinase C (PKC) isoforms are potential targets for breast cancer therapy. This study was designed to evaluate which PKC isoforms might be optimal targets for different breast cancer subtypes.Results: In two cohorts of primary breast cancers, PKCα levels correlated to estrogen and progesterone receptor negativity, tumor grade, and proliferative activity, whereas PKCδ and PKCε did not correlate to clinicopathological parameters. Patients with PKCα-positive tumors showed poorer survival than patients with PKCα-negative tumors independently of other factors. Cell line studies demonstrated that PKCα levels are high in MDA-MB-231 and absent in T47D cells which proliferated slower than other cell lines. Furthermore, PKCα silencing reduced proliferation of MDA-MB-231 cells. PKCα inhibition or downregulation also reduced cell migration in vitro.Conclusions: PKCα is a marker for poor prognosis of breast cancer and correlates to and is important for cell functions associated with breast cancer progression. © 2010 Lønne et al; licensee BioMed Central Ltd.
    Original languageEnglish
    Article number76
    JournalMolecular Cancer
    Volume9
    DOIs
    Publication statusPublished - 14 Apr 2010

    Fingerprint

    Dive into the research topics of 'PKCα expression is a marker for breast cancer aggressiveness'. Together they form a unique fingerprint.

    Cite this